Partnerships Significantly Extend Company Capabilities
At MabVax Therapeutics, we are collaborating with several world-class research and patient treatment organizations. We seek to leverage these valuable relationships by collaborating with leading experts in the field and developing relationships that allow us to sponsor research at these institutions for our current products and explore follow-on product opportunities.
Memorial Sloan Kettering Cancer Center
Memorial Sloan Kettering Cancer Center is one of the world’s leading cancer research hospitals. They have served as an investigative site for the MVT-5873 therapeutic antibody Phase 1 trial. Memorial Sloan Kettering also is the key site for the MVT-2163 PET imaging trial. We have sponsored research and service agreements in place to assist with the preclinical development of several products.
Sarah Cannon Research Institute
Sarah Cannon Research Institute is a leading global clinical research organization focused on cancer. Sarah Cannon offers integrated cancer services and cutting–edge therapies. The Sarah Cannon Research Network provides two investigative sites for our MVT-5873 therapeutic antibody trial.
Rockefeller University is collaborating with MabVax to develop a next-generation HuMab-5B1 antibody. Rockefeller University is a world-renowned center for research and graduate education in the biomedical sciences, chemistry, bioinformatics and physics, and through its unique approach to science has led to some of the world’s most revolutionary contributions to biology and medicine. Our collaboration with Rockefeller is being conducted under the direction of Jeffery Ravetch, M.D., Ph.D., a world-renowned expert on antibodies.
Contact us if you have questions about our company, antibody based therapeutics or any other questions or comments.